Randomized Phase II Trial of Fulvestrant or Exemestane With or Without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer MAINTAIN

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02632045

Study #:
STUDY00144455

Start Date:
Nov 26, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02632045

View Complete Trial Details & Eligibility at ClinicalTrials.gov